Sector News

Integra LifeSciences to spin off spine unit

November 5, 2014
Life sciences
(Reuters) – Surgical devices and orthopedic care company Integra LifeSciences Holdings Corp said it would spin off its spine unit in an attempt to streamline its operations.
 
The company will continue to produce specialty surgical products and orthopedics and tissue therapies, while the new company will be called SeaSpine.
 
The company, which expects to take a one-time charge on the spin-off, revised its full-year profit forecast to 81-99 cents a share, down from its earlier forecast of $1.06 to $1.24 per share.
 
Piper Jaffray & Co. served as the company’s financial advisor, while Latham & Watkins LLP was the legal counsel in connection with the proposed spin-off transaction.
 
(Reporting by Vidya L Nathan in Bangalore; Editing by Joyjeet Das)

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]